Cvfg LLC Takes $6.22 Million Position in argenex SE $ARGX

Cvfg LLC acquired a new position in argenex SE (NASDAQ:ARGX) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 8,517 shares of the company’s stock, valued at approximately $6,220,000.

Several other large investors also recently added to or reduced their stakes in ARGX. AQR Capital Management LLC grew its holdings in shares of argenex by 32.1% during the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after buying an additional 122 shares in the last quarter. NewEdge Advisors LLC boosted its position in argenex by 5,962.5% during the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after acquiring an additional 1,431 shares during the period. Focus Partners Wealth boosted its position in argenex by 22.3% during the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after acquiring an additional 73 shares during the period. Geneos Wealth Management Inc. grew its stake in argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after acquiring an additional 99 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in shares of argenex by 60.2% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock valued at $73,000 after purchasing an additional 50 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Price Performance

NASDAQ ARGX opened at $919.94 on Wednesday. argenex SE has a fifty-two week low of $536.02 and a fifty-two week high of $953.58. The stock’s 50-day moving average is $846.35 and its two-hundred day moving average is $811.75. The firm has a market cap of $57.21 billion, a P/E ratio of 40.96, a price-to-earnings-growth ratio of 1.13 and a beta of 0.45.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. The company had revenue of $1.31 billion during the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%. On average, equities analysts expect that argenex SE will post 26.27 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Guggenheim boosted their price objective on shares of argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Wells Fargo & Company upped their price target on shares of argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research note on Monday, June 1st. Royal Bank Of Canada increased their price objective on argenex from $890.00 to $945.00 and gave the stock an “outperform” rating in a report on Tuesday. Glj Research raised argenex to a “strong-buy” rating in a research report on Friday, April 3rd. Finally, Oppenheimer lowered their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a research note on Thursday, April 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,037.61.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.